Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Current Deferred Revenue: 2024-2025

Historic Current Deferred Revenue for Gossamer Bio (GOSS) over the last 2 years, with Sep 2025 value amounting to $24.0 million.

  • Gossamer Bio's Current Deferred Revenue rose 18.07% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 18.07%. This contributed to the annual value of $17.1 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Gossamer Bio's Current Deferred Revenue stood at $24.0 million, which was up 2.13% from $23.5 million recorded in Q2 2025.
  • Gossamer Bio's Current Deferred Revenue's 5-year high stood at $24.0 million during Q3 2025, with a 5-year trough of $17.0 million in Q2 2024.
  • Over the past 2 years, Gossamer Bio's median Current Deferred Revenue value was $19.1 million (recorded in 2024), while the average stood at $20.0 million.
  • Data for Gossamer Bio's Current Deferred Revenue shows a peak YoY soared of 38.13% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Gossamer Bio's Current Deferred Revenue stood at $17.1 million in 2024, then increased by 18.07% to $24.0 million in 2025.
  • Its Current Deferred Revenue stands at $24.0 million for Q3 2025, versus $23.5 million for Q2 2025 and $17.9 million for Q1 2025.